TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS
https://doi.org/10.14341/osteo2015141-42
Abstract
Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations.
References
1. Ma Y.L., Zeng Q.Q., Chiang A.Y., Burr D., Li J., Dobnig H., Fahrleitner-Pammer A., Michalská D., Marin F., Pavo I., Stepan J.J. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone. 2014 Feb; 59: 139-47. doi: 10.1016/j.bone.2013.11.011.
2. Oswald A.J., Berg J., Milne G., Ralston S.H. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice. Calcif Tissue Int. 2014 Feb; 94(2): 176-82. doi: 10.1007/s00223-013-9788-5.
3. Kyvernitakis I., Kostev K., Kurth A., Albert U.S., Hadji P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int. 2014 Dec; 25(12): 2721-8. doi: 10.1007/s00198-014-2810-6.
4. Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 2014 Dec; 12(4): 385-95. doi: 10.1007/s11914-014-0237-9.
5. Niimi R., Kono T., Nishihara A., Hasegawa M., Matsumine A., Kono T., Sudo A. Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis. Bone. 2014 Sep; 66: 26-30. doi: 10.1016/j.bone.2014.05.017.
6. Krege J.H., Lane N.E., Harris J.M., Miller P.D. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014 Sep; 25(9): 2159-71. doi: 10.1007/s00198-014-2646-0.
Review
For citations:
Pigarova E.A. TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS. Osteoporosis and Bone Diseases. 2015;18(1):41-42. (In Russ.) https://doi.org/10.14341/osteo2015141-42
Views:
4950
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
